INSULET CORP
PODDNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $126.40 β $354.88
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 69.3M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $2.71B
- Last Q Revenue
- $802M
- P/E Ratio
- 27.4
- P/S Ratio
- 3.4x
- EPS (TTM)
- $5.35
- Dividend Yield
- β
- Dilution (1yr)
- β4.6%
INSULET CORP
PODDAbout INSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.